Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

One of the greatest challenges for the treatment of neurodegenerative disease is crossing the blood-brain barrier. Nisbet et al. demonstrate that non-invasive scanning ultrasound increases the delivery of tau-specific single-chain antibody fragments across the blood-brain barrier and into neurons of tau transgenic mice, reducing anxiety-like behaviour and tau pathology.

[1]  Peter Veselcic,et al.  Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology , 2016, Neurobiology of Disease.

[2]  J. Kuo,et al.  Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. , 2016, Radiology.

[3]  Xiaomin Song,et al.  Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease* , 2016, The Journal of Biological Chemistry.

[4]  C. Ising,et al.  Current thinking on the mechanistic basis of Alzheimer's and implications for drug development , 2015, Clinical pharmacology and therapeutics.

[5]  T. Golde,et al.  Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease. , 2015, Human molecular genetics.

[6]  Jürgen Götz,et al.  Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model , 2015, Science Translational Medicine.

[7]  A. Ittner,et al.  Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice , 2015, Journal of neurochemistry.

[8]  E. Sigurdsson,et al.  Antibody-Derived In Vivo Imaging of Tau Pathology , 2014, The Journal of Neuroscience.

[9]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[10]  L. Collin,et al.  Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. , 2014, Brain : a journal of neurology.

[11]  Renu Malhotra,et al.  IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples , 2014, PloS one.

[12]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[13]  T. Golde.  Open questions for Alzheimer’s disease immunotherapy , 2014, Alzheimer's Research & Therapy.

[14]  J. Götz,et al.  Profiling Murine Tau with 0N, 1N and 2N Isoform-Specific Antibodies in Brain and Peripheral Organs Reveals Distinct Subcellular Localization, with the 1N Isoform Being Enriched in the Nucleus , 2013, PloS one.

[15]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[16]  E. Sigurdsson,et al.  Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance* , 2013, The Journal of Biological Chemistry.

[17]  E. Sigurdsson,et al.  Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology* , 2013, The Journal of Biological Chemistry.

[18]  S. Nuttall,et al.  Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity. , 2013, Protein engineering, design & selection : PEDS.

[19]  J. Götz,et al.  Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice , 2013, Neurobiology of Aging.

[20]  Jesús Avila,et al.  GSK3 and tau: two convergence points in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[21]  E. Vázquez,et al.  Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine , 2011, Microbial cell factories.

[22]  I. Landrieu,et al.  Characterization of the AT180 epitope of phosphorylated Tau protein by a combined nuclear magnetic resonance and fluorescence spectroscopy approach. , 2011, Biochemical and biophysical research communications.

[23]  E. Sigurdsson,et al.  Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.

[24]  W. Noble,et al.  Functional Implications of Glycogen Synthase Kinase-3-Mediated Tau Phosphorylation , 2011, International journal of Alzheimer's disease.

[25]  R. Nitsch,et al.  Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, PloS one.

[26]  S. Meairs,et al.  Neurons but not glial cells overexpress ubiquitin in the rat brain following focused ultrasound-induced opening of the blood–brain barrier , 2010, Neuroscience.

[27]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[28]  Rajiv Chopra,et al.  Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease , 2010, PloS one.

[29]  T. Munro,et al.  A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. , 2010, Journal of immunological methods.

[30]  E. Vázquez,et al.  Peptide-assisted traffic engineering for nonviral gene therapy. , 2008, Drug discovery today.

[31]  Jürgen Götz,et al.  Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.

[32]  J. Götz,et al.  Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.

[33]  A. Walf,et al.  The use of the elevated plus maze as an assay of anxiety-related behavior in rodents , 2007, Nature Protocols.

[34]  Bin Yuan,et al.  Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models , 2006 .

[35]  J. Grimm,et al.  Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice , 2006, The Journal of Neuroscience.

[36]  R. Nitsch,et al.  Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice , 2004, Neurobiology of Disease.

[37]  J. Cummings,et al.  Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. , 2003, The Journal of neuropsychiatry and clinical neurosciences.

[38]  J. Cho,et al.  Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. , 2003, The Journal of biological chemistry.

[39]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[40]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[41]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[42]  M. Goedert,et al.  Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. , 1990, The EMBO journal.

[43]  B. Angelsen,et al.  Mechanisms of the ultrasound-mediated intracellular delivery of liposomes and dextrans , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[44]  Yao-Sheng Tung,et al.  Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. , 2010, Ultrasound in medicine & biology.

[45]  R. Bird,et al.  Construction of single-chain Fv derivatives monoclonal antibodies and their production in Escherichia coli. , 1991, Methods in enzymology.

[46]  R. Bird,et al.  [4] Construction of single-chain Fv derivatives of monoclonal antibodies and their production in Escherichia coli , 1991 .